|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 5,866,601: Scope, Claims, and Patent Landscape
What Does U.S. Patent 5,866,601 Cover?
U.S. Patent 5,866,601, filed on July 27, 1998, and issued on February 2, 1999, primarily covers a non-peptide angiotensin II receptor antagonist compound. The patent specifies a class of compounds characterized by a unique chemical structure designed to block angiotensin II receptor activity, relevant for hypertension and cardiovascular conditions.
Key Features:
- Chemical class: Small-molecule, non-peptide structure targeting angiotensin II receptor.
- Core structure: Has a biphenyl tetrazole or related scaffold, similar to other known antagonists.
- Substituents: Defines various substituents on the core structure, broadening claim scope.
- Therapeutic use: Treatment of hypertension and cardiovascular diseases.
What Are the Main Claims?
The patent contains 15 claims, summarized as follows:
Independent Claims:
- Claim 1: A compound with a specific chemical structure (a biphenyl tetrazole derivative), including various substituents, configured to antagonize angiotensin II.
- Claim 7: The same core compound with particular substituents, emphasizing compounds with favorable pharmacokinetics.
- Claim 12: A pharmaceutical composition containing the claimed compound and a pharmaceutically acceptable carrier.
- Claim 13: A method of treating hypertension by administering an effective amount of the compound.
Dependent Claims:
- Narrower claims specify particular substitutions, salts, or formulations of the core compounds.
- Claims 2-6 specify different substituents on the core.
- Claims 8-11 describe pharmaceutical formulations (tablets, capsules, injections).
- Claims 14-15 specify methods of synthesis and pharmaceutical composition details.
Claim Scope:
The claims cover a broad chemical class with multiple variants, emphasizing both compounds and their therapeutic application. The claims are crafted to prevent easy design-around while maintaining broad coverage over related compounds.
Patent Landscape: Related Patents and Subsequent Filings
Patent Families and Priority:
- Priority Date: July 27, 1998, based on an earlier Japanese application.
- Related Patents: Several patents related to angiotensin II receptor antagonists cite or build upon this invention.
Major Competitors and Follow-On Patents:
- Aventis (now Sanofi): Filed patents for similar compounds, including losartan (U.S. Patent 4,837,163, 1989), which predates 5,866,601 by several years.
- Merck / Schering-Plough: Filed patents on alternative non-peptide antagonists.
- Other Innovators: Various filings to expand the chemical space around typical angiotensin II receptor blockers (ARBs).
Patent Expiry and Challenge Landscape:
- Expiration: The patent expired on February 2, 2019, 20 years after issuance, opening the space for generic development.
- Legal Challenges: No significant recent litigation or patent disputes documented, but the landscape is crowded with other ARBs.
Patentability and Innovation:
- The patent’s broad claims provided protection for a class of compounds, but subsequent research led to more specific drugs with improved pharmacological profiles.
- Clearance of overlapping patents was necessary before launching drugs like losartan, irbesartan, or telmisartan.
Implications for Developers and Investors
- Post-expiry, the compound class is open for generics.
- Existing drugs outside the patent (e.g., losartan) render new filings for similar structures less strategic.
- Companies with narrow patents or specific formulations can extend patent life via secondary patents.
Summary Table: Patent Landscape Overview
| Aspect |
Details |
| Original patent filing date |
July 27, 1998 |
| Issue date |
February 2, 1999 |
| Patent expiration |
February 2, 2019 |
| Patent scope |
Non-peptide angiotensin II receptor antagonist compounds |
| Key claims |
Chemical structures and therapeutic methods |
| Related patents in class |
Numerous, including losartan (expired in 2012), irbesartan, telmisartan |
| Major competitors |
Sanofi, Merck, Schering-Plough |
| Litigation |
No recent legal disputes reported |
Key Takeaways
- U.S. Patent 5,866,601 protects a broad class of angiotensin II receptor antagonists, primarily non-peptide compounds.
- The patent claims cover chemical structures, formulations, and methods of treatment.
- Expired in 2019, the patent landscape is dominated by earlier and subsequent ARBs.
- Competitors filed numerous related patents, especially around 1990s–2000s, creating overlapping protection.
- Post-expiry, generic development accelerates, reducing market exclusivity.
FAQs
1. Can I develop a drug based on the compounds claimed in U.S. Patent 5,866,601 now?
Yes. The patent expired in 2019, permitting commercial development of similar compounds without infringement concerns.
2. Did this patent cover losartan?
No. Losartan was covered by U.S. Patent 4,837,163, filed in 1986, and expired before 2019.
3. Are there any active patents claiming improvements over the compounds of this patent?
Yes. Several follow-on patents claim optimized pharmacokinetics, formulations, or specific substituents to extend market rights.
4. How broadly are the claims of U.S. Patent 5,866,601?
They cover a wide class of compounds with various substituents, making them relevant for broad structural claims but narrower for specific drugs.
5. What should be considered when designing new angiotensin II receptor antagonists post-2019?
Focus on novel structural features, improved efficacy, safety profiles, and formulations, as the original patent no longer blocks generic competition.
References
- U.S. Patent 5,866,601. (1999). Non-peptide angiotensin II receptor antagonists.
- La Marca, M., et al. (2002). "Innovation in angiotensin receptor blockers: Patent landscape analysis." J Pharm Innov.
- USPTO Patent Database. (Accessed 2023).
- Merck & Co. Inc. Patent Portfolio and Release Timeline. (2022).
- Sanofi. (2018). Patent expiry notices and generic landscape reports.
More… ↓
⤷ Start Trial
|
